Financial Performance - The company's operating revenue for Q1 2022 was RMB 20,538,509 thousand, representing a year-on-year increase of 2.46%[2] - Net profit attributable to shareholders for the same period was RMB 1,805,641 thousand, showing a year-on-year increase of 10.95%[2] - Total revenue for Q1 2022 reached RMB 20,538,508,775.79, an increase of 2.45% compared to RMB 20,045,948,581.48 in Q1 2021[15] - Operating profit for Q1 2022 was RMB 2,262,817,891.86, up from RMB 2,037,565,977.89 in Q1 2021, reflecting a growth of 11.05%[16] - Net profit attributable to shareholders for Q1 2022 was RMB 1,891,545,920.06, compared to RMB 1,704,046,593.50 in Q1 2021, representing an increase of 10.98%[16] - The total net profit for Q1 2022 was RMB 1,891,545,920.06, an increase from RMB 1,704,046,593.50 in Q1 2021, reflecting a growth of approximately 11%[38] - The total comprehensive income for Q1 2022 was RMB 1,890,082,467.60, compared to RMB 1,700,330,078.41 in Q1 2021, indicating an increase of about 11%[41] Earnings and Shareholder Information - The basic and diluted earnings per share for the quarter were both RMB 1.111, reflecting a year-on-year increase of 10.95%[2] - Earnings per share for Q1 2022 were RMB 1.111, compared to RMB 1.001 in Q1 2021, indicating a growth of 11.00%[19] - The total number of ordinary shareholders at the end of the reporting period was 95,051[7] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares, totaling 732,305,103 shares[7] Assets and Liabilities - The total assets at the end of the reporting period were RMB 67,042,055 thousand, an increase of 1.40% from the previous year[3] - The total liabilities of the company as of March 31, 2022, were RMB 33,829,739,933.10, a decrease from RMB 34,791,121,204.96 as of December 31, 2021, showing a reduction of about 2.77%[13] - The company's total current assets amounted to RMB 53,344,071,856.06, an increase from RMB 52,810,574,461.45 as of December 31, 2021, reflecting a growth of approximately 1.01%[11] - The company's total assets increased to RMB 67.04 billion as of March 31, 2022, compared to RMB 66.12 billion at the end of 2021, reflecting a growth of about 1.4%[36] - The total liabilities decreased to RMB 33.83 billion as of March 31, 2022, from RMB 34.79 billion at the end of 2021, a reduction of approximately 2.8%[35] Cash Flow - The net cash flow from operating activities decreased by 45.40% to RMB 918,064 thousand compared to the previous year[6] - The cash inflow from operating activities totaled RMB 18,514,442,197.50, while cash outflow was RMB 17,596,378,357.22, resulting in a net cash flow from operating activities of RMB 918,063,840.28[20] - The cash flow from investment activities showed a net outflow of RMB 429,198,901.93 in Q1 2022, compared to a net outflow of RMB 145,023,681.83 in Q1 2021[21] - The cash flow from financing activities resulted in a net inflow of RMB 848,637,912.69 in Q1 2022, down from RMB 1,193,058,613.18 in Q1 2021[21] - The net cash flow generated from operating activities in Q1 2022 was RMB 918,063,840.28, down from RMB 1,681,290,433.57 in Q1 2021, a decline of about 45%[42] Research and Development - Research and development expenses for Q1 2022 were RMB 238,880,428.92, compared to RMB 186,120,919.54 in Q1 2021, reflecting a growth of 28.38%[15] - Research and development expenses for Q1 2022 were RMB 238.88 million, up from RMB 186.12 million in Q1 2021, representing a growth of about 28.4%[37] Other Financial Metrics - Non-recurring gains and losses for the period amounted to RMB 31,561 thousand, with government subsidies contributing RMB 21,612 thousand[4] - Other comprehensive income after tax attributable to the parent company was RMB (1,123,941.08) in Q1 2022, compared to RMB (3,077,457.91) in Q1 2021, showing an improvement[17] - The weighted average return on equity for Q1 2022 was 6.03%, a slight decrease of 0.01 percentage points compared to the previous year[24] - The company reported a decrease in accounts payable to RMB 10.33 billion as of March 31, 2022, down from RMB 11.29 billion at the end of 2021, a decline of approximately 8.5%[35] Inventory and Receivables - Accounts receivable increased to RMB 13,869,274,804.25 from RMB 12,816,537,107.40, representing a growth of approximately 8.21%[11] - The company's inventory decreased to RMB 8,731,127,537.83 from RMB 10,437,733,799.99, representing a decline of approximately 16.30%[11]
白云山(00874) - 2022 Q1 - 季度财报